Yet another important investment in the field of regenerative medicine against aging demonstrates the increasing interest of investors in this industry; on August 2, BioTime, Inc. announced that Juvenescence Limited will buy 14.4 million of its subsidiary AgeX Therapeutics‘ shares for a total of $43.2 million—50% to be paid in cash and 50% with a…

July is here, and our upcoming conference in New York City is only a handful of days away! If you haven’t done so already, go and get your ticket now so that you can enjoy the June roundup fully relaxed, knowing that your seat is secured. About our NYC conference On the off chance you’ve…

We were interested to learn that Juvenescence Limited, a biotech and development company involved in the development of therapies that target the aging processes, has successfully raised $50 million in a series A financing round. Jim Mellon, the chairman of Juvenescence Limited, said, “We are delighted with the progress we have made and the faith…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD